Symbols

AGEN

Agenus·NASDAQ

--(--)

AGEN Profile

Agenus Inc.

An immuno-oncology company with a broad pipeline targeting cancer and infectious disease

Industry

Biological Technology

Established Date

Listing Date

02/04/2000

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.agenusbio.com

Security Type

Common stock

Office address

3 Forbes Road, Lexington, Massachusetts 02421

Business

Introduction

Agenus Inc., founded in 1994, is a Delaware limited liability company. The company is a clinical-stage biotechnology company specializing in the development of therapies that activate the human immune system to fight cancer and infection. Their main clinical program is botensilimab, including monotherapy and combination therapy with balstilimab. They also have some clinical-stage immuno-oncology assets that can be used as stand-alone drugs or in combination with botensilimab and balstilimab.